BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
IVDs on the rise
Radiopharmaceuticals
Science '22 in Review
Top Biopharma Trends of 2022
Top Med-tech Trends of 2022
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, October 4, 2023
See today's BioWorld
Home
» Lonza acquires ADC firm Synaffix for $108M up front, $65M in milestones
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Lonza acquires ADC firm Synaffix for $108M up front, $65M in milestones
June 1, 2023
By
Cormac Sheridan
No Comments
Lonza Group Ltd. has acquired Synaffix BV, the developer of a widely partnered set of tools for generating antibody-drug conjugates (ADCs), for €100 million (US$108 million) up front plus up to €60 million more in milestones.
BioWorld
Deals and M&A
Cancer
